Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Stock Information for Galectin Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galectin Therapeutics Inc.

Cassava Reports Q3 2025 Financials Results and Provides Business Update
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Cassava Reports Q1 2025 Financials Results, Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.